Base Year
Historical Year
Forecast Year
The global idiopathic pulmonary fibrosis treatment market size attained a value of USD 3.59 billion in 2023, driven by growing cases of lung diseases, increasing geriatric population, and rising patient awareness, which is likely to propel the demand for idiopathic pulmonary fibrosis treatment. The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to attain a value of USD 5.96 billion by 2032.
The industry is expected to attain a value of USD 4.3 billion by 2026. The market is being dominated by the North America and European regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Idiopathic pulmonary fibrosis (IPF) refers to a severe lung disease. As you breathe in, oxygen travels through tiny airbags in your lungs and into your bloodstream. This flows to the organs from there. IPF causes scar tissue to develop within the lungs, making it hard to breathe. The treatment of this disease can help in slowing down the damage to the lungs.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The idiopathic pulmonary fibrosis treatment market can be broadly categorised based on drug class into:
The EMR report looks into the regional markets for idiopathic pulmonary fibrosis like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increased prevalence of idiopathic pulmonary fibrosis (IPF) and the increasing geriatric population are the key drivers of the market. The increase in the number of people smoking cigarettes, leading to a high prevalence of IPF, is also projected to fuel the growth of the market.
The report presents a detailed analysis of the following key players in the global market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Marketed Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global market for idiopathic pulmonary fibrosis treatment reached a value of USD 3.59 billion.
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to reach a value of USD 5.96 billion by 2032.
The major drivers of the market include the growing prevalence of lung conditions, increasing geriatric population, and rising patient awareness which is likely to propel the demand for idiopathic pulmonary fibrosis treatment.
The increasing number of smokers, which is leading to a rise in prevalence of IPF (idiopathic pulmonary fibrosis) and pollution-triggered lung conditions are expected to be key trends guiding the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Pirfenidone and nintedanib are the different drug-classes in the global idiopathic pulmonary fibrosis treatment market.
The major players in the market are Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., and F. Hoffmann-La Roche Ag, among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share